Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Globus Medical Inc. (NYSE:GMED), a medical device company with a market capitalization of $12 billion and an "GREAT" financial health rating according to InvestingPro, reaffirmed its commitment to ...

Canaccord Genuity maintained a Buy rating with a $101.00 price target for Globus Medical (NYSE:GMED) shares, which currently trades at $88.54. The firm's analysis supports the company's ongoing ...

Globus Medical is acquiring Nevro Corp, a spinal cord stimulator company, according to a Feb. 6 news release. Globus Medical's transaction will include all shares of Nevro, which are valued at about ...

Stryker sold its U.S. spinal implants to the Viscogliosi Brothers, and market analysts with GlobalData predict the move will benefit competitors in spinal fusio ...

In a pioneering approach to achieve fusion energy, the SMART device has successfully generated its first tokamak plasma. This step brings the international fusion community closer to achieving ...

and the PsiFGuard device co-developed with Omnia Medical for sacroiliac fusion which recently obtained FDA clearance. The Company is also pursuing the registering process of the whole PediGuard ...